SVCP
REGN icon

Silicon Valley Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Silicon Valley Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.11K Hold
4
– – ﹤0.01% 262
2025
Q4 		$3.1K Hold
4
– – ﹤0.01% 238
2025
Q3 		$2.26K Hold
4
– – ﹤0.01% 260
2025
Q2 		$2.11K Hold
4
– – ﹤0.01% 278
2025
Q1 		$2.55K Hold
4
– – ﹤0.01% 228
2024
Q4 		$2.85K Buy
+4
New +$3.36K ﹤0.01% 293

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Silicon Valley Capital Partners's REGN Position: Q1 2026 in Review

Silicon Valley Capital Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 4 shares worth $3.11K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

Silicon Valley Capital Partners first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Silicon Valley Capital Partners held 4 shares of Regeneron Pharmaceuticals worth $3.11K as of Q1 2026.
  • Silicon Valley Capital Partners left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q1 2026, its #262 holding.
  • Silicon Valley Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2026, filed 19 May 2026.